Fingerprint
Dive into the research topics of 'Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Benny Johnson, Cara L. Haymaker, Edwin R. Parra, Luisa Maren Solis Soto, Xuemei Wang, Jane V. Thomas, Arvind Dasari, Van K. Morris, Kanwal Raghav, Eduardo Vilar, Bryan K. Kee, Cathy Eng, Christine M. Parseghian, Robert A. Wolff, Younghee Lee, Daniele Lorenzini, Caddie Laberiano-Fernandez, Anuj Verma, Wenhua Lang, Ignacio I. Wistuba
Research output: Contribution to journal › Article › peer-review
18
Scopus
citations